In terms of recurrence time, the results revealed that glioma patients with high Siglec15 expression had a shortened PFS compared with those with low expression (HR [95% CI], 1.87 [1.51–2.32], P < 0001, Figure 2B). Here, SIGLEC15 is linked to glioma.